Marksans Pharma Statistics

Total Valuation

Marksans Pharma has a market cap or net worth of INR 114.45 billion. The enterprise value is 110.84 billion.

Market Cap	114.45B
Enterprise Value	110.84B

Important Dates

The last earnings date was Friday, May 30, 2025.

Earnings Date	May 30, 2025
Ex-Dividend Date	Sep 17, 2024

Share Statistics

Current Share Class	453.16M
Shares Outstanding	n/a
Shares Change (YoY)	-0.02%
Shares Change (QoQ)	+0.02%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	214.46M

Valuation Ratios

The trailing PE ratio is 30.07 and the forward PE ratio is 23.52.

PE Ratio	30.07
Forward PE	23.52
PS Ratio	4.36
PB Ratio	4.60
P/TBV Ratio	4.86
P/FCF Ratio	339.15
P/OCF Ratio	55.38
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 20.97, with an EV/FCF ratio of 328.47.

EV / Earnings	29.12
EV / Sales	4.23
EV / EBITDA	20.97
EV / EBIT	24.89
EV / FCF	328.47

Financial Position

The company has a current ratio of 4.62, with a Debt / Equity ratio of 0.13.

Current Ratio	4.62
Quick Ratio	2.63
Debt / Equity	0.13
Debt / EBITDA	0.61
Debt / FCF	9.54
Interest Coverage	38.19

Financial Efficiency

Return on equity (ROE) is 16.73% and return on invested capital (ROIC) is 10.83%.

Return on Equity (ROE)	16.73%
Return on Assets (ROA)	9.40%
Return on Invested Capital (ROIC)	10.83%
Return on Capital Employed (ROCE)	16.12%
Revenue Per Employee	22.99M
Profits Per Employee	3.34M
Employee Count	1,141
Asset Turnover	0.89
Inventory Turnover	1.56

Taxes

In the past 12 months, Marksans Pharma has paid 1.21 billion in taxes.

Income Tax	1.21B
Effective Tax Rate	24.08%

Stock Price Statistics

The stock price has increased by +49.77% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+49.77%
50-Day Moving Average	234.97
200-Day Moving Average	262.15
Relative Strength Index (RSI)	51.01
Average Volume (20 Days)	112,864

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Marksans Pharma had revenue of INR 26.23 billion and earned 3.81 billion in profits. Earnings per share was 8.40.

Revenue	26.23B
Gross Profit	14.79B
Operating Income	4.45B
Pretax Income	5.04B
Net Income	3.81B
EBITDA	5.29B
EBIT	4.45B
Earnings Per Share (EPS)	8.40

Full Income Statement

Balance Sheet

The company has 7.05 billion in cash and 3.22 billion in debt, giving a net cash position of 3.83 billion.

Cash & Cash Equivalents	7.05B
Total Debt	3.22B
Net Cash	3.83B
Net Cash Per Share	n/a
Equity (Book Value)	24.89B
Book Value Per Share	54.49
Working Capital	17.27B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 2.07 billion and capital expenditures -1.73 billion, giving a free cash flow of 337.45 million.

Operating Cash Flow	2.07B
Capital Expenditures	-1.73B
Free Cash Flow	337.45M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 56.39%, with operating and profit margins of 16.98% and 14.51%.

Gross Margin	56.39%
Operating Margin	16.98%
Pretax Margin	19.21%
Profit Margin	14.51%
EBITDA Margin	20.16%
EBIT Margin	16.98%
FCF Margin	1.29%

Dividends & Yields

This stock pays an annual dividend of 0.60, which amounts to a dividend yield of 0.24%.

Dividend Per Share	0.60
Dividend Yield	0.24%
Dividend Growth (YoY)	n/a
Years of Dividend Growth	2
Payout Ratio	7.14%
Buyback Yield	0.02%
Shareholder Yield	0.26%
Earnings Yield	3.33%
FCF Yield	0.29%

Dividend Details

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

The last stock split was on March 11, 2008. It was a forward split with a ratio of 10.

Last Split Date	Mar 11, 2008
Split Type	Forward
Split Ratio	10

Scores

Altman Z-Score	n/a
Piotroski F-Score	4